Chen Z, Zhang Y, Zhang X, Du G, Yang W, Hu Z, Li J, Zhang Y
Department of Urology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan 430030.
J Tongji Med Univ. 2001;21(1):56-8. doi: 10.1007/BF02888038.
The expression of multidrug resistant proteins in bladder cancer and clinical implication was studied. Expression of multidrug-associated protein (MRP), P-glycoprotein (P-gp), P53 and Bcl-2 proteins were detected by using immunohistochemical method in 40 specimens of bladder transitional cell carcinoma. The results showed that the positive rate of MRP, P-gp, P53 and Bcl-2 was 52.5%, 57.5%, 47.5% and 62.5% respectively. The positive rate of MRP, P-gp, P53 and Bcl-2 in the grade I, II and III of tumors was 46.3%, 38.5%, 38.5%, 23.1%; 52.9%, 39.8%, 47.1%, 76.4%; 60.0%, 80.0%, 60.0%, 90.0% respectively. The positive rate of MRP, P-gp, P53 and Bcl-2 in 24 primary tumor specimens was 37.5%, 41.7%, 33.3%, 45.8% and that in 16 cases in recurrent specimens receiving chemotherapy 75.0%, 81.3%, 68.8%, 87.5% respectively. It was suggested the positive rate of MRP, P-gp, P53 and Bcl-2 was increased with the advance of tumor grade. The positive rate of four proteins in all recurrent cases was significantly increased (P < 0.05). The expression of MRP, P-gp, P53 and Bcl-2 proteins might be the important factors for chemotherapy failure.
研究了多药耐药蛋白在膀胱癌中的表达及其临床意义。采用免疫组织化学方法检测40例膀胱移行细胞癌标本中多药相关蛋白（MRP）、P-糖蛋白（P-gp）、P53和Bcl-2蛋白的表达。结果显示，MRP、P-gp、P53和Bcl-2的阳性率分别为52.5%、57.5%、47.5%和62.5%。肿瘤Ⅰ级、Ⅱ级和Ⅲ级中MRP、P-gp、P53和Bcl-2的阳性率分别为46.3%、38.5%、38.5%、23.1%；52.9%、39.8%、47.1%、76.4%；60.0%、80.0%、60.0%、90.0%。24例原发性肿瘤标本中MRP、P-gp、P53和Bcl-2的阳性率分别为37.5%、41.7%、33.3%、45.8%，16例接受化疗的复发病例中其阳性率分别为75.0%、81.3%、68.8%、87.5%。提示MRP、P-gp、P53和Bcl-2的阳性率随肿瘤分级的升高而增加。所有复发病例中这四种蛋白的阳性率均显著升高（P<0.05）。MRP、P-gp、P53和Bcl-2蛋白的表达可能是化疗失败的重要因素。
